CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • NBIX Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 8-K Filing

Neurocrine Biosciences (NBIX) 8-KNeurocrine Biosciences Reports Second Quarter 2021 Financial Results

Filed: 3 Aug 21, 4:02pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • 99.1 Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
    • Download Excel data file
    • View Excel data file
    Related financial report
    • 2021 Q2 Quarterly report
    NBIX similar filings
    • 23 Dec 21 Other Events
    • 22 Nov 21 Entry into a Material Definitive Agreement
    • 1 Nov 21 Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
    • 3 Aug 21 Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
    • 21 May 21 Submission of Matters to a Vote of Security Holders
    • 5 May 21 Neurocrine Biosciences Reports First Quarter 2021 Financial Results
    • 16 Apr 21 Departure of Directors or Certain Officers
    Filing view
    Share this filing

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): August 3, 2021
    NEUROCRINE BIOSCIENCES, INC.
    (Exact name of Registrant as Specified in Its Charter)
    Delaware0-2270533-0525145
    (State or Other Jurisdiction(Commission(IRS Employer
    of Incorporation)File Number)Identification No.)
    12780 El Camino Real,
    San Diego,California92130
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s Telephone Number, Including Area Code: (858) 617-7600
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange on which registered
    Common Stock, $0.001 par valueNBIXNasdaq Global Select Market
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 2.02. Results of Operations and Financial Condition.
    On August 3, 2021, Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2021. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
    Item 9.01. Financial Statements and Exhibits.
    ExhibitDescription
    99.1
    Press Release dated August 3, 2021
    104Cover Page Interactive Data File



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     NEUROCRINE BIOSCIENCES, INC.
      
    Dated: August 3, 2021/s/ Matthew C. Abernethy
     Matthew C. Abernethy
     Chief Financial Officer
    (Duly authorized officer and Principle Financial Officer)

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn